Table 1 Relationships between clinical features and ACSL1 expression in ccRCC patients in TCGA data sets

n

269

270

T stage, n (%)

T1

121 (22.4%)

157 (29.1%)

T2

38 (7.1%)

33 (6.1%)

T3

102 (18.9%)

77 (14.3%)

T4

8 (1.5%)

3 (0.6%)

N stage, n (%)

N0

116 (45.1%)

125 (48.6%)

N1

12 (4.7%)

4 (1.6%)

M stage, n (%)

M0

204 (40.3%)

224 (44.3%)

M1

50 (9.9%)

28 (5.5%)

Pathologic stage, n (%)

Stage I

115 (21.5%)

157 (29.3%)

Stage II

30 (5.6%)

29 (5.4%)

Stage III

69 (12.9%)

54 (10.1%)

Stage IV

53 (9.9%)

29 (5.4%)

Primary therapy outcome, n (%)

PD

7 (4.8%)

4 (2.7%)

SD

2 (1.4%)

4 (2.7%)

PR

0 (0%)

2 (1.4%)

CR

51 (34.7%)

77 (52.4%)

Gender, n (%)

Female

69 (12.8%)

117 (21.7%)

Male

200 (37.1%)

153 (28.4%)

Race, n (%)

Asian

6 (1.1%)

2 (0.4%)

Black or African American

29 (5.5%)

28 (5.3%)

White

232 (43.6%)

235 (44.2%)

Age, n (%)

<=60

141 (26.2%)

128 (23.7%)

> 60

128 (23.7%)

142 (26.3%)

Histologic grade, n (%)

G1

5 (0.9%)

9 (1.7%)

G2

96 (18.1%)

139 (26.2%)

G3

110 (20.7%)

97 (18.3%)

G4

54 (10.2%)

21 (4%)

Laterality, n (%)

Left

126 (23.4%)

126 (23.4%)

Right

142 (26.4%)

144 (26.8%)

OS event, n (%)

Alive

156 (28.9%)

210 (39%)

Dead

113 (21%)

60 (11.1%)

DSS event, n (%)

Alive

180 (34.1%)

240 (45.5%)

Dead

83 (15.7%)

25 (4.7%)

PFI event, n (%)

Alive

158 (29.3%)

220 (40.8%)

Dead

111 (20.6%)

50 (9.3%)

Serum calcium, n (%)

Elevated

6 (1.6%)

4 (1.1%)

Low

103 (28.1%)

100 (27.3%)

Normal

79 (21.6%)

74 (20.2%)

Hemoglobin, n (%)

Elevated

3 (0.7%)

2 (0.4%)

Low

147 (32%)

116 (25.3%)

Normal

88 (19.2%)

103 (22.4%)

Age, mean ± SD

60.04 ± 12.32

61.21 ± 11.86